

























Development of Innovative Gene Therapy Candidate for Hepatocellular Carcinoma Targeting High-Risk Dual-Specific Protein Phosphatase

CUROGEN Technology

Disease Area	Oncology																		
Product Type	[Gene therapy] CR-G001; AAV8 expressing CR-P1 under the control of hepatocyte selective TBG promoter																		
Indication	Hepatocellular Carcinoma (MASH-associated and HBV-positive HCC)																		
Target	CR-P1 (Code name)																		
Mechanism of Action	<ul style="list-style-type: none"> Inactivation of hepatocellular carcinoma cells <ul style="list-style-type: none"> Recovery from hepatocyte damage Inhibition of hepatic oncogenic cell cycle Improvement of anti-tumor immunity <ul style="list-style-type: none"> Improvement of anti-tumor activity of macrophage Improvement of CD8⁺ T cell cytotoxic & effector function 																		
Competitiveness	<ul style="list-style-type: none"> First-in-class HCC gene therapy Excellent treatment efficacy with single injection in various HCC murine models Better therapeutic interventions compared to mtTKIs and ICIs Substantial improvement of modality with combined (mtTKI and ICI) treatments 																		
Development Stage	Lead																		
Route of Administration	Portal vein or hepatic artery injection																		
Key Data	<div style="display: flex; justify-content: space-between;"> <div style="width: 20%;">  <p>AAV8 CR-P1 CR-G001</p> </div> <div style="width: 60%;"> <p>Promoter gene dependent in vivo expression of CR-G001</p> <table border="1"> <thead> <tr> <th></th> <th>AAV8-CMV-Empty</th> <th>AAV8-CMV-CR-P1</th> <th>AAV8-TBG-CR-P1</th> </tr> </thead> <tbody> <tr> <td>IHC:HA</td> <td></td> <td></td> <td></td> </tr> <tr> <td>HA-tag positive area</td> <td></td> <td></td> <td></td> </tr> </tbody> </table> <p>Scale bar = 300 μm</p> </div> <div style="width: 20%;"> <p>Efficacy of CR-G001 in oncogene-induced HCC model</p> <table border="1"> <tbody> <tr> <td>AAV8-TBG (Control)</td> <td></td> <td></td> </tr> <tr> <td>AAV8-TBG -CR-P1 (CR-G001)</td> <td></td> <td></td> </tr> </tbody> </table> <p>Scale bar = 1 cm</p> </div> </div>		AAV8-CMV-Empty	AAV8-CMV-CR-P1	AAV8-TBG-CR-P1	IHC:HA				HA-tag positive area				AAV8-TBG (Control)			AAV8-TBG -CR-P1 (CR-G001)		
	AAV8-CMV-Empty	AAV8-CMV-CR-P1	AAV8-TBG-CR-P1																
IHC:HA																			
HA-tag positive area																			
AAV8-TBG (Control)																			
AAV8-TBG -CR-P1 (CR-G001)	